It’s hard to believe that the biotech sector, known for its inherent volatility, is an island of relative stability in an increasingly volatile stock market. Read More

Now that the Memorial Day weekend is in our rear view mirror, it is fair to ask if the old stock market adage, “Sell in May and then go away” will turn out to be good advice for tech stocks this year. They certainly have had a very nice run… Read More

Now that first quarter earnings season is mostly completed, here is an update on some of the Next Wave Portfolio holdings:Paycom Software (PAYC)—With the stock last week seeing a sharp increase in volatility, I am raising the stop loss to $33.50. In case the shares have hit a short-term peak,… Read More

Resources are tightening up and that means that any new drugs that come to the market and deliver tangible financial results have to live up to a higher standard than before. Read More

Recently we added Dr. Joe Duarte to our research team at Smart Tech Investor, and have been very impressed with his insight and analysis. Although we realize the biotech sector has appreciated considerably during the past year and may be due for a correction, we feel the long term upside… Read More

Most mega acquisitions usually only sound good on paper—once completed they almost never work out as planned. Read More

Equity Trades Portfolio Updateby Joe Duarte, M.D.Buy AlertsEarnings UpdateNews Update: It’s ASCO Conference SeasonM & A UpdateThe biotech sector rebounded on the week that ended on May 8th. Behind another merger announcement and some mixed economic news, the worries about the Federal Reserve raising interest rates… Read More